Jennifer Sims-Mourtada, PhD
Senior Clinical Scientist
Center for Translational Cancer Research
Helen F. Graham Cancer Center
Christiana Care Health System
Newark, DE, USA
Dr. Sims-Mourtada is the Director of Translational Breast Cancer Research in the Center for Translational Research at the Helen F Graham Cancer Center and Research Institute, Christiana Care Health Services, Inc, located in Newark, DE. She is also an appointment as a adjunct Associate Professor in the Department of Medical Laboratory Sciences, College of Health Sciences at the University of Delaware. She received her PhD in Immunology in 2004 from the University of Texas Graduate School of Biomedical Sciences and completed her post-doctoral training in Radiation Biology at The University of Texas MD Anderson Cancer Center. Prior to joining the HFGCCRI, she served as Director of Molecular Research and Development for RadioMedix, Inc. located in Houston TX.
Her research seeks to provide insight as to what drives growth and treatment resistance in aggressive breast cancers, particularly factors which influence cancer stem cell growth and plasticity.
HONORS AND AWARDS
• (1993)-Present) Member of National Golden Key Honor Society
• (1998-2004) Recipient of R.E. Smith Predoctoral Fellowship for research in the field of Cancer Immunology
• (2005-2006) Recipient of Postdoctoral Traineeship Award - Department of Defense Prostate Cancer Research Program
• (2006) Travel award, 3rd Annual Gastrointestinal Oncology Conference, International Society of Gastrointestinal Oncology, Arlington, VA
• Radiation Research Society, (2006)
• International Society of Gastrointestinal Oncology, (2006)
• American Association of Cancer Researchers (AACR) (2007-present)
• Society of Nuclear Medicine (SNM) (2007-present)
• American Society for Therapeutic Radiation and Oncology (ASTRO) (2007-present)
• Society of Molecular Imaging (SMI) (2009-present)
1. Sims MJ, Davis OL, Arnold J, Flynn KD. Taxane induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy. Molecular Carcinogenesis. doi: 10.1002/mc.22225.
2. Smith DL, Yang KF, Larson RD, Sims MJ, Woodward W. Hedgehog targeting peptides for imaging and therapy of breast cancer. Biomed Research International .
3. Sims MJ, Niamat RA, Samuel S, Eskridge C, Kmiec EB. Enrichment of breast cancer stem-like cells by growth on electrospun polycaprolactone-chitosan nanofiber scaffolds. International Journal of Nanotechnology. 2014; 9(1): 995-1003. doi: 10.2147/IJN.S55720.
4. Smith DL, Breeman WAP, Sims MJ. The untapped potential of 68-Gallium-PET: the next wave of 68-gallium agents. Journal of Applied Radiation and Isotopes. 2012; 29(12): 537-544. doi: 10.1016/j.apradiso.2012.10.014
5. SimsMJ, Yang D, Tworowka I, et al. Detection of canonical hedgehog signaling in breast cancer by 131-Iodine-labeled derivatives of the sonic hedgehog protein. Journal of Biomedicine and Biotechnology. 2012; 2012: 639562 doi: 10.1155/2012/639562.
6. Delpassand E, Samarghandi A, Sims MJ, et al. Long-term survival and toxicity profile of patients with progressive neuroendocrine tumors following Peptide Receptor Radionuclide Therapy with high activity 111In pentetreotide. Theranostics. 2012; 2(5):472-480 doi: 10.7150/thno.3739.
7. McKeller MR, Herrera RS, Ma W, et al. Vital function of PRELI and essential requirement of its LEA motif. Cell Death and Disease. 2010; (1): 1-13. doi: 10.1038/cddis.2009.19.
8. Delpassand ES, Sims MJ, Saso H, et al. Safety and efficacy of radionuclide therapy with multiple 500 mCi doses of In-111 Pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biotherapy and Radiopharmaceuticals. 2008; 23(3): 292-300. doi: 10.1089/cbr.2007.0448.
9. Sims MJ, Azhdarinia A, Yang DJ, Mourtada F. Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer Current Molecular Imaging Reviews: 2008; 4(1): 28-33.
10. Yang DY, Chandra M, Sims MJ, Azhdarinia A, Oh CS, Kim E. Challenges and Opportunities in Molecular Imaging. Current Molecular Imaging Reviews. 2008; 4(1): 46-50.
11. Izzo JG, Luthra R, Sims MJ, et al. Emerging Molecular Targets in Esophageal Cancer. GastroIntestinal Cancer Research. 2007; 1(4): S3-S6.
12. Chen YJ, Sims MJ, Izzo JG, Chao KSC. Targeting the Hedgehog Pathway to mitigate treatment resistance. Cell Cycle. 2007: 6(15): 1826-1830. doi: 10.4161/cc.6.15.4545
13. Sims MJ, Izzo JG, Ajani JA, Chao KSC. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007; 26(38): 5674-5679. doi: 10.1038/sj.onc.1210356
14. Sims MJ, Izzo JG, Apisarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clinical Cancer Research. 2006; 12(21): 6565-6572. doi: 10.1158/1078-0432.CCR-06-0176
15. Sims MJ, McKellarMR, Martinez VH, et al. The human AKNA gene maps to chromosome 9q32.1, expresses alternatively spliced transcripts and translates into overlapping protein isoforms . DNA Cell Biol. 2005; 24(5): 325-338.
16. Rangel R, McKeller MR, Sims MJC, et al. Assemble of the k PreB receptor requires the Vk- like protein encoded by germline transcripts. J Biol Chem. 2005; 280(18): 17807-17814.
17. Sims MJC, Guzman RL, Rangel R, et al. In vivo expression of interleukin-8, and RANTES by human germinal centre B lymphocytes. Immunology. 2003; 110(3): 296-303. doi: 10.1046/j.1365-2567.2003.01745.x
18. Guzman RL, Sims MJC, Rangel R, Martinez VH. Life and death within germinal centers: a double-edged sword. Immunology. 2002; 107: 167-175. doi: 10.1046/j.1365-2567.2002.01494.x
19. Siddiqa A, Sims MJ, Guzman RL, et al. Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA. Nature. 2001; 41: 383-387. doi: 10.1038/35066602
20. Guzman RL, Sims JC, Rangel R, et al. PRELI, the human homologue of the avian px19, is expressed by germinal center B lymphocytes. Int Immunol. 2000; 12: 607-612. doi: 10.1093/intimm/12.5.607
21. Sims-Mourtada J, Opdenaker LM, Davis J, Wu C. Long term, low dose Genistein decreases stem cell populations and sensitizes inflammatory breast cancer cell lines to radiation. Cancer Stud Mol Med Open J. 2015; 2(1): 60-65.
21. Mourtada F, Sims-Mourtada J. Boosting response: the impact of immune checkpoint inhibitors on radiation treatment schedules. Cancer Stud Mol Med Open J. 2015; 2(2): e8-e10. doi: < a href= http://openventio.org/Volume2_Issue2/Boosting_Response_The_Impact_of_Immune_Checkpoint_Inhibitors_on_Radiation_Treatment_Schedules_CSMMOJ_2_e002.pdf target=_blank>10.17140/CSMMOJ-2-e002
22. Sims-Mourtada J, Opdenaker LM, Davis J, Wu C. Long term, low dose Genistein decreases stem cell populations and sensitizes inflammatory breast cancer cell lines to radiation. Cancer Stud Mol Med Open J. 2015; 2(1): 60-65. doi: 10.17140/ CSMMOJ-2-107
23. Mourtada F, Sims-Mourtada J. Boosting response: the impact of immune checkpoint inhibitors on radiation treatment schedules. Cancer Stud Mol Med Open J. 2015; 2(2): e8-e10. doi: 10.17140/CSMMOJ-2-e002
24. Arnold KM, Flynn NJ, Sims-Mourtada J. Activation of inflammatory responses correlate with hedgehog activation and precede expansion of cancer stem-like cells in an animal model of residual triple negative breast cancer after neoadjuvant chemotherapy. Cancer Stud Mol Med Open J. 2015; 2(2): 80-86. doi: 10.17140/CSMMOJ-2-112